Daniel Schreeder, MD
Hematology & Oncology · Huntsville, ALNPI 1457650848
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (49.6%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 54 manufacturers reported payments, led by Gilead at 43.4% of the total. Reporting peaked in 2022 at $7,169 and has fallen 55.4% since, to $3,199 in 2025.
Across 261 payments — averaging $59.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$7K
- AstraZeneca$2K
- Johnson & Johnson$2K
- Novartis$472
- Pfizer$464
- Seagen Inc.$464
- plus $4K from 48 others
Across 41 payments — averaging $2472.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Jazz Pharmaceuticals Inc.$76K
- Novartis$13K
- Ipsen Bioscience Inc.$12K
What the payments were for
- Consulting fees$7,69550%
- Speaking & faculty fees$1201%
- Travel & lodging$1,80012%
- Food & beverage$5,30534%
- Education$1721%
- Other$4323%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,525 in reported general payments places this provider in the 70th percentile of 177 hematology & oncology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 76 | $1,251,005 |
| XtandiEnzalutamide | 45 | $566,874 |
| Lenalidomide | 42 | $565,135 |
| TruqapCapivasertib | 13 | $294,469 |
| LenvimaLenvatinib Mesylate | 12 | $291,709 |
| VerzenioAbemaciclib | 15 | $212,783 |
| NubeqaDarolutamide | 15 | $201,639 |
| KisqaliRibociclib Succinate | 13 | $198,509 |
| BrukinsaZanubrutinib | 13 | $172,705 |
| PomalystPomalidomide | 11 | $168,250 |
| EliquisApixaban | 209 | $150,643 |
| ErleadaApalutamide | 11 | $145,077 |
| TasignaNilotinib Hcl | 12 | $114,936 |
| TrazimeraTrastuzumab-Qyyp | 42 | $108,258 |
| Udenyca AutoinjectorPegfilgrastim-Cbqv | 26 | $102,508 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $270 | $1,251,00576 claims |
| PfizerEliquis, Trazimera, Bosulif | $464 | $317,429263 claims |
| NovartisKisqali, Tasigna | $472 | $313,44625 claims |
| AstraZenecaTruqap | $1,904 | $294,46913 claims |
| Eisai Inc.Lenvima | $59 | $291,70912 claims |
| Lilly USA, LLCVerzenio, Olanzapine | $23 | $213,08959 claims |
| BayerNubeqa | $74 | $201,63915 claims |
| Johnson & JohnsonErleada, Xarelto | $1,775 | $190,12576 claims |
| Beigene USA, Inc.Brukinsa | $56 | $172,70513 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $268 | $168,25011 claims |
| AmgenNeulasta | $19 | $95,28515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 177 hematology & oncology providers in Alabama.
Other hematology & oncology in Huntsville
- Ehab ElbaheshHuntsville$47K
- Ali HachemHuntsville$20K
- Jorge Diaz CastroHuntsville$14K
- Amitkumar MehtaBirmingham$683K
- Pankit VachhaniBirmingham$545K
- Luciano CostaBirmingham$409K
- Khaleel AshrafBirmingham$379K
- Michael BirrerBirmingham$302K
- Rudolph NavariBirmingham$254K
- Mayur NarkhedeBirmingham$193K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.